Abbott Q1 adj. EPS $1.15, +6% YoY; acquires Exact Sciences; FY guidance $5.38-$5.58

ABBOTT LABORATORIES

2026-Q1 EPS reported $0.61 revenue$11,164,000,000

Q1 GAAP diluted EPS $0.61; adjusted diluted EPS $1.15 (+6% YoY).
Q1 sales $11.16B, reported +7.8%, comparable +3.7%.
Completed Exact Sciences acquisition March 23; adds $0.20 dilution to FY EPS guidance.
FY2026 guidance: comparable sales growth 6.5%-7.5%; adjusted EPS $5.38-$5.58.
Medical Devices +8.5% comparable; Diabetes CGM +7.6% comparable; Nutrition -7.7% comparable.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ABBOTT LABORATORIES updated its first quarter ended March 31, 2026 guidance (reaffirmed).

Period: first quarter ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026.

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

ABBOTT LABORATORIES filing history →

Source: SEC EDGAR

accession 0001628280-26-025365

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.